The FDA has approved Priorix (measles, mumps and rubella [MMR] vaccine, live; GSK) active immunization for the prevention of measles, mumps, and rubella (MMR) in individuals 12 months of age and older. Priorix can be administered as a first dose, followed by a second dose of the vaccine, or as a second dose to those previously administered the first dose of another MMR-containing vaccine.
The efficacy of Priorix was demonstrated based on immunogenicity data versus the comparator vaccine, according to GSK. The vaccine is set to be on the agenda this month for review by the CDC Advisory Committee on Immunization Practices for consideration of formal inclusion into the vaccine schedule and recommendations.